SynthesisFrontiers in pharmacology2024
Global trends of antimicrobial resistance rates in
Synthesis in Frontiers in pharmacology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 13 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Antimicrobial Resistance inMedicina (Kaunas, Lithuania) · 2026Pooled it
- Machine learning models in predicting antimicrobial resistance in gonorrhea: a systematic review and meta-analysis.Frontiers in public health · 2026Pooled it
- Global patterns of antibiotic resistance in group BFrontiers in microbiology · 2025Pooled it
- Trends and risk factors of antimicrobial resistance of Neisseria gonorrhoeae in Catalonia, Spain, 2022-2023.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Article
- Identification of antigonorrhoeal phytochemical lead compounds using a metabolomics-guided approach.Folia microbiologica · 2026Article
- Assessing N. gonorrhoeae prevalence and testing capacity for new treatment rollout: a scoping review for Cambodia, Thailand, Vietnam and South Africa.BMC infectious diseases · 2026Article
- Synergistic Effect of the Mucosa-Friendly Agents Berberine and Tea Tree Oil on Mucosal Protection AgainstAntibiotics (Basel, Switzerland) · 2026Article
- [Superbugs Neisseria gonorrhoeae und Mycoplasma genitalium : Therapeutic challenges driven by antimicrobial resistance].Dermatologie (Heidelberg, Germany) · 2026Review
- Global genomic and antimicrobial resistance profiling of Neisseria gonorrhoeae: Insights from whole genome sequencing and minimum inhibitory concentration analysis.PLoS neglected tropical diseases · 2025Article
- Tetracycline-resistantJAC-antimicrobial resistance · 2025Review
- Routine Treatment Versus Selective Treatment for Individuals Reporting Contact With Sexual Partners With Chlamydia: A Before-and-After Study.The Journal of infectious diseases · 2025Article
- Article
- Expanded Gram-Negative Activity of Marinopyrrole A.Pathogens (Basel, Switzerland) · 2025Article
Corrections and comments
- Erratum issued
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Antimicrobial resistance (AMR) of Objective: The objective of our study was to assess global AMR rates and test them both temporally and geographically. Methods: We conducted a systematic search of relevant reports from international databases up to 2021. The R statistical package was used for all statistical analyses. Results: A total of 225 articles were analyzed, and 432,880 NG isolates were examined. The weighted pooled resistance (WPR) rate of different antibiotics was as follows: ciprofloxacin, 51.6%; tetracycline, 45.4%; trimethoprim/sulfamethoxazole, 42.4%; chloramphenicol, 4.1%; kanamycin, 2.1%; gentamicin, 0.6%; and spectinomycin, 0.3%. The resistance to spectinomycin, gentamicin, and kanamycin decreased over time. Significant differences in antibiotic resistance rates were found between the countries. Conclusion: Our findings reveal a continuous increase in resistance to some antibiotics (tetracycline and ciprofloxacin) historically used for gonorrhea, even after discontinuation. However, encouraging trends of decreasing resistance to spectinomycin, gentamicin, and kanamycin were observed. Continued global monitoring of AMR profiles in NG isolates is essential for informing appropriate treatment strategies and mitigating the threat of untreatable gonorrhea.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.